Search the repository

A+ | A- | | SLO | ENG

Abstract: The role of FoxP3+ regulatory T cells (Tregs) in the tumour microenvironment (TME) of peripheral T-cell lymphomas (PTCLs) is complex, and their impact on overall survival (OS) is unclear. This retrospective study aims to examine the quantity of FoxP3+ cells in the TME of PTCLs and reactive lymph nodes (LNs) and their impact on OS. A lower FoxP3+ cell quantity is found in PTCLs compared to reactive LNs. While differences in OS are observed between groups with high and low FoxP3+ cell quantities using various cut-off values, further analyses show no significant impact on the risk of death. This study suggests FoxP3+ cells as potential prognostic biomarkers but recommends the conduction of larger, multicentre studies with standardized protocols for confirmation. It also indicates that Treg-suppressing drugs may not be suitable for certain PTCL patients. Instead, combining therapies, including those enhancing Treg function, could be more effective in improving outcomes for PTCL patients, warranting further research.
Keywords: lymphoma, prognostic biomarkers, overall survival
Published in DiRROS: 09.01.2025; Views: 637; Downloads: 150
Full text (3,45 MB)
This document has many files! More...

Abstract: Background. Sclerosing melanocytic lesions, which are characterized by either focal or diffuse sclerosis in the dermal component and atypical proliferation of predominantly nevoid melanocytes, remain poorly defined. Our aim was to analyze systematically their morphologic spectrum, especially the distinction between sclerosing melanocytic nevus and sclerosing melanoma, which has not been well documented. Patients and methods. We collected 90 sclerosing melanocytic lesions, occurring in 82 patients (49 male, 33 female; age range from 21 to 89 years). A four probe fluorescent in situ hybridization (FISH) assay was performed in 41 lesions to substantiate the diagnosis of sclerosing melanomas. Results. A prominent full-thickness pagetoid spread of melanocytes was identified in 44 (48%) lesions, and a melanoma in situ adjacent to the sclerosis in 55 (61%) lesions. In the intrasclerotic component, maturation was absent in 40 (44%) and mitotic figures were identified in 18 (20%) lesions. Of the 90 lesions, 26 (29%) were diagnosed morphologically as nevi and 64 (71%) as melanomas (Breslow thickness from 0.4 to 1.8 mm), including 45 (50%) melanomas with an adjacent nevus. A four-probe FISH assay was positive in the sclerotic component in 14 of 25 lesions diagnosed morphologically as melanomas and none of 16 nevi. A sentinel lymph node biopsy was performed for 17 lesions and was negative in all cases. Conclusions. Sclerosing melanocytic lesions form a morphologic spectrum and include both nevi and melanomas. The pathogenesis of sclerosis remains obscure but seems to be induced by melanocytes or an unusual host response in at least a subset of lesions.
Keywords: sclerosing melanoma, sclerosing nevus, fibrosis
Published in DiRROS: 02.07.2024; Views: 592; Downloads: 283
Full text (1,34 MB)

Abstract: High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are known for their aggressive clinical course and so are the ones with MYC and BCL2 protein overexpression. The optimal therapy for these lymphomas remains to be elucidated. A retrospective analysis of all diffuse large B-cell lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements diagnosed between 2017 and 2021 at the Institute of Oncology Ljubljana, Slovenia, has been performed. Only patients with double-expressor lymphoma (DEL), double-hit lymphoma (DHL), or triple-hit lymphoma (THL) were included. Demographic and clinical parameters were assessed, as well as progression-free survival (PFS) and overall survival (OS). In total, 161 cases out of 309 (161/309; 52,1%) were classified as DEL. Sixteen patients had DHL, MYC/BCL2 rearrangement was observed in eleven patients, and MYC/BCL6 rearrangement was observed in five patients. Five patients were diagnosed with THL. Out of 154 patients (according to inclusion/exclusion criteria) included in further evaluation, one-hundred and thirty-five patients had double-expressor lymphoma (DEL), sixteen patients had DHL, and three patients had THL. In total, 169 patients were treated with R-CHOP, 10 with R-CHOP and intermediate-dose methotrexate, 19 with R-DA-EPOCH, and 16 with other regimens. The median follow-up was 22 months. The 5-year OS for the whole DEL group was 57.1% (95% CI 45.9–68.3%) and the 5-year PFS was 76.5% (95% CI 72.6–80.4%). The log-rank test disclosed no differences in survival between treatment groups (p = 0.712) while the high-risk international prognostic index (IPI) carried a significantly higher risk of death (HR 7.68, 95% CI 2.32–25.49, p = 0.001). The 5-year OS for DHL patients was 32.4% (95% CI 16.6–48.2%) while all three TH patients were deceased or lost to follow-up. Our analyses of real-life data disclose that the R-CHOP protocol with CNS prophylaxis is a successful and curative treatment for a substantial proportion of DEL patients.
Keywords: lymphoma, double-expressor lymphoma, oncology
Published in DiRROS: 18.04.2024; Views: 720; Downloads: 402
Full text (1004,13 KB)
This document has many files! More...

Keywords: onkologija, rak dojke, patologija
Published in DiRROS: 14.02.2023; Views: 1049; Downloads: 301
Full text (79,90 KB)

Keywords: onkologija, rak dojke, patologija
Published in DiRROS: 14.02.2023; Views: 970; Downloads: 252
Full text (107,23 KB)